Centers for Medicare and Medicaid Services

Selected news for the healthcare topic - Centers for Medicare and Medicaid Services, collected since 10/2017. This healthcare topic shares news with Seema Verma, COVID-19, Public Health, Medicare Advantage, Department of Health and Human Services and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/13/2022 Medicare Proposes to Restrict Coverage of Controversial and Costly Alzheimer's Drug Yahoo News ... Äôs Aduhelm, a monoclonal antibody treatment for Alzheimer‚Äôs, which has faced questions about both its cost and its effectiveness. The decision also applies to similar drugs in development.The preliminary proposal by the Centers for Medicare and Medicaid Services (CMS) is highly unusual. ‚ÄúCMS almost never demands such trials for a drug already approved by the Food and Drug Administration,‚Äù The Washington Post‚Äôs Laurie McGinley and Amy ...
1/12/2022 Medicare proposes coverage limits for Alzheimer's drug Aduhelm – KIRO 7 News Seattle kiro7.com ... the memory-robbing disease.”Specifically, the drug is designed to trigger an immune response that reduces the formation and build-up of amyloid plaques, the newspaper reported.Tuesday’s initial determination from the Centers for Medicare and Medicaid Services means that patients taking Aduhelm will have to participate in research efforts to assess the drug’s effectiveness. The ruling will not be finalized until the spring, however, following a ...
1/12/2022 Montana Psych Hospital Failed to Properly Investigate Death | Montana News | U.S. News & World Report ... a patient who was reportedly told to go back to her room "and stop being dramatic," after she told staff she was having trouble catching her breath, a federal report said.Investigators with the Centers for Medicare and Medicaid Services also found the Montana State Hospital in Warm Springs has inadequate staffing, resulting in a lack of patient supervision that led to 113 reported falls on one unit of the ...
1/12/2022 Ticker: ARPA infusion boosts fuel aid; Medicare limits coverage of Alzheimer's drug Boston Herald ... Committee.Medicare limits coverage of Alzheimer’s drugMedicare said Tuesday it will limit coverage of a $28,000-a-year Alzheimer’s drug whose benefits have been widely questioned.The initial determination from the Centers for Medicare and Medicaid Services means that patients taking Biogen’s Aduhelm medication will have to be part of research efforts to assess the drug’s effectiveness in slowing the progression of dementia. Medicare’s ...
1/12/2022 Medicare limits coverage of $28,000-a-year Alzheimer's drug – Boston Herald Boston Herald ... been widely questioned, a major development in the nation’s tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices.The initial determination from the Centers for Medicare and Medicaid Services means that for Medicare to pay, patients taking Biogen’s Aduhelm medication will have to be part of clinical trials to assess the drug’s effectiveness in slowing the progression ...
1/12/2022 Biogen Stock Slumps As Medicare Limits Alzheimer's Drug Coverage - TheStreet TheStreet Biogen ( BIIB ) - Get Biogen Inc. Report shares slumped lower Wednesday after the U.S. government's Medicare program said it will limit access to the drugmaker's newly-approved Alzheimer's treatment. The U.S. Centers for Medicare and Medicaid Services said it will only cover treatment with Aduhelm, Biogen's Alzheimer's treatment, if patients are enrolled in a clinical trial. The decision, which could be ...
1/12/2022 Medicare proposes to cover controversial Alzheimer's drug with restrictions Philly Tribune Medicare has proposed covering the controversial and costly Alzheimer's drug Aduhelm only for those enrolled in qualifying clinical trials, the Centers for Medicare and Medicaid Services announced Tuesday.The draft decision, the latest step in the drug's contentious path to market, would have far-reaching consequences both for millions of Alzheimer's patients and for tens of millions of Medicare enrollees . A final decision should be released by April 11."CMS ...
1/12/2022 Why Biogen Stock Is Sinking Today | Nasdaq Nasdaq What happened Shares of Biogen (NASDAQ: BIIB) were sinking 9.5% as of 10:48 a.m. ET on Wednesday. The decline came after the Centers for Medicare and Medicaid Services (CMS) on Tuesday released its proposed National Coverage Determination (NCD) for Biogen's Alzheimer's disease drug Aduhelm. The proposed NCD would only cover Aduhelm for Medicare beneficiaries enrolled in clinical trials.So what Biogen had hoped that CMS would decide to provide full ...
1/12/2022 Medicare limits coverage of $28,000-a-year Alzheimer's drug wtmj.com ... been widely questioned, a major development in the nation’s tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices.The initial determination from the Centers for Medicare and Medicaid Services means that for Medicare to pay, patients taking Biogen’s Aduhelm medication will have to be part of clinical trials to assess the drug’s effectiveness in slowing the progression ...
1/12/2022 Medicare limits coverage of $28,000-a-year Alzheimer's drug wtmj.com ... been widely questioned, a major development in the nation’s tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices.The initial determination from the Centers for Medicare and Medicaid Services means that for Medicare to pay, patients taking Biogen’s Aduhelm medication will have to be part of clinical trials to assess the drug’s effectiveness in slowing the progression ...
1/12/2022 Medicare limits coverage of $28,000-a-year Alzheimer's drug daytondailynews.com ... have been widely questioned, a major development in the nation’s tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices.The initial determination from the Centers for Medicare and Medicaid Services means that for Medicare to pay, patients taking Biogen’s Aduhelm medication will have to be part of clinical trials to assess the drug’s effectiveness in slowing the progression ...
1/12/2022 Biogen Stock Is Tumbling Because Its Aduhelm Drug Has Hit Another Snag - MarketWatch MarketWatch ... program proposed Tuesday evening.If approved, the decision would restrict access to the first Alzheimer’s therapy approved in decades by the Food and Drug Administration.Dr. Lee Fleisher, chief medical officer of the Centers for Medicare and Medicaid Services , said in a news release announcing the draft ruling that even though the drug shows promise, it could also harm patients. “This harm may range from headaches, dizziness, and falls ...
1/12/2022 Medicare proposes restricting coverage of Alzheimer's drug Aduhelm to clinical trials - UPI.com upi.com Jan. 11 (UPI) -- Medicare officials on Tuesday decided a new Alzheimer's drug will be covered only for patients participating in approved clinical trials.In a preliminary decision , the Centers for Medicare and Medicaid Services said the federal health insurance program should cover the Alzheimer's drug Aduhelm only for use in "CMS-approved randomized controlled trials" and trials supported by the National Institutes of Health. Advertisement"All trials must be conducted ...
1/12/2022 Medicare limits coverage of $28,000-a-year Alzheimer's drug wral.com ... been widely questioned, a major development in the nation’s tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices.The initial determination from the Centers for Medicare and Medicaid Services means that for Medicare to pay, patients taking Biogen’s Aduhelm medication will have to be part of clinical trials to assess the drug’s effectiveness in slowing the progression ...
1/12/2022 Medicare proposes restricting coverage of Alzheimer's drug to clinical trials - NewsBreak newsbreak.com Jan. 11 (UPI) -- Medicare officials on Tuesday decided a new Alzheimer's drug will be covered only for patients participating in approved clinical trials.In a preliminary decision , the Centers for Medicare and Medicaid Services said the federal health insurance program should cover the Alzheimer's drug Aduhelm only for use in "CMS-approved randomized controlled trials" and trials supported by the National Institutes of Health."All trials must be conducted in ...
1/12/2022 Medicare limits coverage of $28,000-a-year Alzheimer's drug - Chicago Sun-Times suntimes.com ... been widely questioned, a major development in the nation’s tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices.The initial determination from the Centers for Medicare and Medicaid Services means that for Medicare to pay, patients taking Biogen’s Aduhelm medication will have to be part of clinical trials to assess the drug’s effectiveness in slowing the progression ...
1/12/2022 Medicare limits coverage of $28,000-a-year Alzheimer's drug thebusinessjournal.com ... been widely questioned, a major development in the nation’s tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices.The initial determination from the Centers for Medicare and Medicaid Services means that for Medicare to pay, patients taking Biogen’s Aduhelm medication will have to be part of clinical trials to assess the drug’s effectiveness in slowing the progression ...
1/12/2022 Medicare limits coverage of $28,000-a-year Alzheimer's drug - Albuquerque Journal abqjournal.com ... been widely questioned, a major development in the nation’s tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices.The initial determination from the Centers for Medicare and Medicaid Services means that for Medicare to pay, patients taking Biogen’s Aduhelm medication will have to be part of clinical trials to assess the drug’s effectiveness in slowing the progression ...
1/12/2022 Medicare won’t cover controversial Alzheimer's drug — unless patients are in a clinical trial - NewsBreak newsbreak.com The Centers for Medicare and Medicaid Services announced Tuesday that it would cover Biogen’s controversial Alzheimer’s treatment that was approved by the Food and Drug Administration in June — but only for those who enroll in ongoing clinical trials.The proposed rule means that many older Americans with early-stage Alzheimer‘s disease will not have access to the drug, which targets amyloid build-ups in the brain ...
1/12/2022 Medicare proposes limited coverage for controversial Alzheimer's treatment | Washington Examiner Washington Examiner T he Centers for Medicare and Medicaid Services announced that it would only cover the expensive new Alzheimer’s treatment from Biogen for patients enrolled in clinical trials, significantly limiting the patient population that could benefit from it.“CMS has proposed an evidence-based coverage policy after experts reviewed all relevant publicly available evidence and feedback received from stakeholders,” said CMS Administrator Chiquita Brooks-LaSure.The treatment, marketed by ...